Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Issued
Ratios

Heron Therapeutics (HRTX) Receivables - Other (2020 - 2025)

Heron Therapeutics' Receivables - Other history spans 6 years, with the latest figure at $160000.0 for Q4 2025.

  • For Q4 2025, Receivables - Other fell 39.16% year-over-year to $160000.0; the TTM value through Dec 2025 reached $160000.0, down 39.16%, while the annual FY2025 figure was $160000.0, 39.16% down from the prior year.
  • Receivables - Other reached $160000.0 in Q4 2025 per HRTX's latest filing, down from $263000.0 in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $6.2 million in Q4 2022 to a low of $21000.0 in Q4 2023.
  • Average Receivables - Other over 5 years is $1.3 million, with a median of $160000.0 recorded in 2025.
  • Peak YoY movement for Receivables - Other: skyrocketed 5916.5% in 2022, then crashed 99.66% in 2023.
  • A 5-year view of Receivables - Other shows it stood at $103000.0 in 2021, then surged by 5916.5% to $6.2 million in 2022, then plummeted by 99.66% to $21000.0 in 2023, then soared by 1152.38% to $263000.0 in 2024, then crashed by 39.16% to $160000.0 in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Receivables - Other are $160000.0 (Q4 2025), $263000.0 (Q4 2024), and $21000.0 (Q4 2023).